Table 1.

In vitro susceptibilities of select aerobic and anaerobic organisms to tigecycline^a

Organism	No. of isolates	MIC90b	MIC rangeb	% Susceptiblec	References
Staphylococcus aureus	8765	0.5	≤0.016–1	99.4	(Sader et al 2005)
MSSA	813	0.12	0.015–0.5	100	(Waites et al 2006)
MRSA	879	0.25	0.03–0.5	100	(Waites et al 2006)
VISA	19	0.5	0.06–1	NAd	(Petersen et al 2002)
Staphylococci, coagulase-negative (CoNS)	3570	0.5	≤0.016–2	97.5	(Sader et al 2005)
CoNS, methicillin susceptible	71	0.5	0.03–1	NAd	(Fritsche, Sader et al 2005)
CoNS, methicillin resistant	189	0.5	≤0.12–2	NAd	(Fritsche, Sader et al 2005)
S. pneumoniae	605	≤0.12	≤0.12–1	--e	(Sader et al 2005)
S. pneumoniae, penicillin susceptible	279	0.5	NAd	NAd	(Hoban et al 2005)
S. pneumoniae, penicillin-resistant	54	0.25	NAd	NAd	(Hoban et al 2005)
Streptococci, β-hemolytic	769	≤0.12	≤0.12–0.5	99.7	(Sader et al 2005)
Streptococci, viridans group	378	≤0.12	≤0.12–0.05	98.1	(Sader et al 2005)
Enterococci spp.	3258	0.25	≤0.016–2	92.7	(Sader et al 2005)
Enterococcus spp.-vancomycin susceptible	466	0.5	≤0.12–1	NAd	(Fritsche, Sader et al 2005)
Enterococcus spp.-vancomycin resistant	39	0.25	0.03–0.5	NAd	(Fritsche, Sader et al 2005)
Nocardia spp.	51	4	≤0.06–8	NAd	(Cercenado et al 2007)
Escherichia coli	3217	0.25	0.03–4	>99.9	(Sader et al 2005)
ESBL-producing E.coli	115	0.38	0.047–0.75	NAd	(Sorlozano et al 2006)
Klebsiella pneumonia	1334	2	≤0.008–8	95	(Waites et al 2006)
ESBL-producing	126	2	0.12–8	92.1	(Waites et al 2006)
K. pneumoniae
Klebsiella oxytoca	248	1	0.06–4	98.8	(Waites et al 2006)
Enterobacter aerogenes	419	1	0.06–8	95.7	(Waites et al 2006)
Enterobacter cloacae	1089	2	≤0.008–8	93	(Waites et al 2006)
Haemophilus influenzae	336	0.25	NAd	--e	(Hoban et al 2005)
H. influenzae, β-lactamase positive	93	0.25	NAd	--e	(Hoban et al 2005)
Moraxella catarrhalis	54	0.5	NAd	--e	(Gales et al 2005)
Serratia marscens	658	1	0.012–8	97	(Waites et al 2006)
Citrobacter spp.	252	0.5	NAd	86.9	(Fritsche, Strabala et al 2005)
Acinetobacter baumannii	851	1	0.03-8	--e	(Waites et al 2006)
Pseudomonas aeruginosa	1338	≥32	≤0.008–≥32	--e	(Waites et al 2006)
Stenotrophomonas maltophilia	203	2	0.12–8	--e	(Sader et al 2005)
Burkholderia cepacia	21	16	0.25–32	--e	(Cheng et al 2005)
Campylobacter jejuni	108	4	0.12–16	--e	(Rodriguez-Avial et al 2006)
Campylobacter coli	8	16	0.5–16	--e	(Rodriguez-Avial et al 2006)
Proteus mirabilis	320	4	0.25–16	46.9	(Sader et al 2005)
Bacteroides fragilis	2721	8	0.06–32	94.9	(Snydman et al 2007)
Bacteroides fragilis group	5225	8	0.06–64	95.7	(Snydman et al 2007)
B. distasonis	274	8	0.25–32	97.9	(Snydman et al 2007)
B. ovatus	545	8	0.125–16	96.7	(Snydman et al 2007)
B. thetaiotaomicron	978	8	0.25–32	96.4	(Snydman et al 2007)
B. vulgatus	306	4	0.25–16	98.4	(Snydman et al 2007)
C. perfringens	51	1.0	≤0.06–2	NAd	(Bradford et al 2005)
Clostridium difficile	12	0.06	0.06	NAd	(Goldstein et al 2006)
Fusobacterium varium	13	0.25	0.06–0.25	NAd	(Goldstein et al 2006)
Lactobacillus spp.	15	0.5	0.06–1	NAd	(Goldstein et al 2006)

^aAdapted with permission from (Townsend ML et al 2006. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract, 60:1662–72. Blackwell Publishing.)

^bMIC = minimum inhibitory concentration.

^cAccording to CLSI criteria.

^dNA = not available.

^eNo CLSI criteria available.